Luca Gallelli was born in Naples on November 03 1973 and he graduated in Medicine and Surgery at the University of Reggio Calabria, Italy on 1997. In the same year he started the PhD program in Pharmacology and Toxycology (Chemiotherapy) at the Second University of Naples, Italy. During this period, he studied the lung function in vivo and in vitro models. He improved his learning (lung function in animal models and in cell culture (fibroblasts, bronchial epithelial cells, cancer cells) in London at the Department of Pharmacology King’s College London (directed by Prof C.P. Page), and at the Department of Pulmonary Pharmacology in Faculty of Medicine Paris Ouest, Francia (directed by Prof C. Advenier), In 2005 he obtained the degree as Specialist in Clinical Pharmacology at the School of Medicine University of Catanzaro. From 2007 to date, he works in Pharmacology at the University of Catanzaro, Italy, and his field of expertise are Clinical pharmacology, clinical toxicology, drug use
EDUCATION
degree in medicine and surgery,
PhD in Pharmacology and Toxicology (Chemotherapy) in Second University of Naples, Italy,
Specialist in Clinical Pharmacology, School of Medicine University of Catanzaro
Postgraduate Course in Quality Organization & Personnel Management in Public Health, acquired at the "Magna Graecia" University of Catanzaro
1st Level Theoretical and Practical Course in Oxygen Ozone therapy. Organized by the Italian Society of Oxygen Ozone Therapy
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmacology (medical), General Medicine, Pharmacology, Toxicology and Pharmaceutics, Pharmacology
328
Scopus Publications
Scopus Publications
Prostate health supporting by a novel nutraceutical compound with antioxidant property: Results from a pilot study Claudio Marino, Marco Magliocchetti, Dario Di Lieto, Erika Cione, Cristina Vocca, Tommaso Ceccato, Simone Botti, Fabrizio Palumbo, Luca Gallelli, Tommaso Cai Urologia Journal, 2026 In recent years, healthcare strategies have increasingly emphasized a holistic and comprehensive approach in patient management that extends beyond the treatment of isolated physical symptoms. In this context, the use of nutraceuticals has gained interest as a complementary approach, particularly in managing chronic conditions and age-related disorders, such as lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). A new dietary supplement, contains a blend of bio-active compounds (Drolessano ® )—including lycopene, sulforaphane, silymarin, glutathione, escine, tryptophan, and green tea extract—has been introduced in Italian pharmacopeia as food supplements in urological and andrological diseases. Here, we aim to assess the effects of Drolessano ® on serum prostate-specific antigen (PSA) levels and urinary symptoms in individuals with BPH. Fifty-five men presenting with elevated PSA values and mild lower urinary tract symptoms (International Prostate Symptom Score [IPSS] < 7) were recruited in this pilot study. All enrolled patients underwent Drolessano ® one tablet daily for 6 months. PSA concentrations and IPSS scores were recorded at baseline (T0), at 3 months (T1), and at the end of the treatment period (T2). Data at the follow-up has been compared with those at baseline. Patients enrolled experienced a statistical significance average PSA declined from 4.8 to 3.7 ng/mL ( p < 0.003), as well as in improvement of quality of life, tested by patient reported outcomes. The supplement was generally well tolerated, and no serious adverse effects were reported during the study period. These preliminary data suggest that Drolessano ® may offer a supportive benefit in the management of BPH, particularly with respect to reducing PSA levels and improvement quality of life. Otherwise, controlled trials with larger sample sizes are needed to substantiate these findings and to better understand the underlying mechanisms of action.
Inflammatory Biomarkers Are Associated with Pain and Functional Impairment in Knee Osteoarthritis Patients: A Cross-Sectional Pilot Study Luca Gallelli, Vincenzo Rania, Roberta Macrì, Mirza Suljagic, Andzelika Michniewicz, Daria Ler, Gianmarco Marcianò, Cristina Vocca, Caterina Palleria, Domenica Scumaci, Diana Marisol Abrego-Guandique, Maria Cristina Caroleo, Erika Cione Journal of Clinical Medicine, 2026 Background: Osteoarthritis (OA) is a heterogeneous joint disorder traditionally considered mechanically driven; however, evidence indicates that inflammatory mechanisms contribute to symptom expression. Exploratory analyses of peripheral biomarkers may provide insights into systemic inflammation in symptomatic knee OA, but formal phenotypic validation requires dedicated clustering or longitudinal studies. Objective: To examine associations between clinical pain, functional impairment, and circulating inflammatory biomarkers in patients with knee OA compared with healthy controls. Methods: In this prospective, single-center study, patients aged 40–80 years with radiographically confirmed knee OA and chronic knee pain were compared with age- and sex-matched healthy controls. Pain intensity and functional status were assessed using the Visual Analogue Scale (VAS) and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Circulating inflammatory biomarkers, including cytokines and matrix metalloproteinases, were quantified using multiplex immunoassays. Statistical analyses included adjusted linear regression models, with age and BMI as covariates, and multiple testing correction using the Benjamini–Hochberg procedure (FDR alpha error 5%). Results: OA patients exhibited higher circulating levels of TNF-α, IL-6, IL-8, MMP-1, MMP-3, TNFSF13, TNFSF13B, and pentraxin-3 compared with controls (p < 0.01). No significant sex differences were observed. KOOSs correlated with IL-6 and IL-10 levels, suggesting an association between systemic inflammatory activity and functional limitation. All findings are presented as exploratory and associative. Conclusions: Patients with knee OA display systemic inflammatory biomarker differences associated with pain and functional impairment. These results support the role of inflammation in OA symptoms within an exploratory framework. Larger, longitudinal studies are warranted to validate these observations.
The Effectiveness and Safety of a New Nutraceutical in Patients with Knee Osteoarthritis: A Pilot Study Cristina Vocca, Vincenzo Rania, Gianmarco Marcianò, Caterina Palleria, Lucia Muraca, Laura Gallelli, Davida Mirra, Diana Marisol Abrego-Guandique, Maria Cristina Caroleo, Erika Cione, Luca Gallelli Nutraceuticals, 2026 Background: Nutraceuticals are increasingly used in clinical practice for their anti-inflammatory, antiproliferative, and antioxidant properties. This study aimed to evaluate the safety and efficacy of a fixed nutraceutical combination containing chondroitin sulfate, α-lipoic acid, astaxanthin, lycopene, escin, and omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in improving pain and quality of life in patients with chronic knee osteoarthritis (OA). Methods: This observational study included patients with chronic knee OA who were referred to the ambulatory pain clinic at Dulbecco University Hospital, Catanzaro, Italy. Participants received one tablet daily for three months. Quality of life was assessed using the 36-Item Short Form Health Survey (SF-36), and adverse drug reactions (ADRs) were evaluated using the Naranjo scale. Results: Fifty patients (20 men and 30 women; mean age, 63.6 ± 11.4 years; range, 26–88 years; mean body mass index, 26.9 ± 3.7 kg/m2) were enrolled. Pain symptoms demonstrated a statistically significant improvement over time (p < 0.01). No ADRs were reported during the study period. Conclusions: The fixed nutraceutical combination improved pain and quality of life in patients with chronic knee OA and demonstrated an excellent safety profile.
Managing Gut Dysbiosis: Clinical Evidence and Perspectives on Saccharomyces boulardii CNCM I-745 for Diarrhoeal Conditions in Adults and Children Gerardo Pio Nardone, Arrigo Francesco Giuseppe Cicero, Luca Gallelli, Roberto Berni Canani Microorganisms, 2026 The human gut microbiota plays a key role in health and disease across the lifespan and is shaped by complex intrinsic and extrinsic factors. Dysbiosis is increasingly recognized as a contributor to a wide range of clinical conditions, with diarrhoea—particularly antibiotic-associated diarrhoea—representing an early clinical marker of microbiota disruption. This narrative review summarizes current evidence on the probiotic yeast Saccharomyces boulardii CNCM I-745 and its clinical applications in both paediatric and adult populations. Available clinical data support its safety and efficacy in the prevention and management of gastrointestinal disorders, particularly diarrhoeal conditions, and suggest a potential role in promoting microbiota resilience. Key mechanisms of action, safety considerations, and findings from randomized controlled trials and meta-analyses are discussed. However, current data remains limited by heterogeneity among studies and a lack of long-term, mechanistic data, highlighting the need for further well-designed studies to clarify its role across different clinical settings.
Resolution of post-traumatic lumbar disc herniation following diamagnetic therapy: a case report Vincenzo Rania, Davide Stanà, Caterina Palleria, Gianmarco Marcianò, Cristina Vocca, Luca Gallelli Pain Management, 2026 Lumbar disc herniation is a common cause of low back pain leading to significant functional impairment. High-intensity, low-frequency pulsed electromagnetic field (Diamagnetic therapy) gained attention to treating several diseases. We report a 47-year-old man with severe post-traumatic low back pain radiating bilaterally to the lower limbs (VAS: 8; Douleur-Neuropathique-4: 5/10). MRI showed an annulus fibrosus fissure and a partially extruded left paramedian L4-L5 disc herniation compressing the dural sac. Pharmacological treatments (NSAIDs, corticosteroids, opioids, muscle relaxants) and physical therapy (Capacitive and resistive electric transfer therapy) provided no benefit. At presentation to our Pain Room, clinical findings included positive Lasegue at 30°, bilateral Valleix signs, paraspinal tenderness, and significant quality-of-life impairment (SF-36). The patient underwent a full course of diamagnetic therapy after providing written informed consent and following ethics committee approval. After 16 sessions (twice weekly, 20 minutes each; high-intensity fluids off/biostimulation), the VAS score decreased to 0/10 and the Douleur-Neuropathique-4 to 0/10, with MRI evidence of herniation resorption. This case illustrates that diamagnetic therapy improved the patient's clinical condition in refractory post-traumatic low disc herniation, supporting its potential as a promising noninvasive option for selected patients, although further controlled studies are required to confirm its efficacy.
Exploring the Role of Cissus quadrangularis in Osteoporosis Management Nicola Manocchio, Andrea Sorbino, Antonio Devito, Luca Gallelli, Daniele Romanello, Sara Rotunno, Calogero Foti, Alberto Migliore Orthopedic Research and Reviews, 2026 (CQ) is a Vitaceae-derived medicinal plant rich in flavonoids, phytosterols, triterpenoids, vitamins, and bone-relevant minerals, conferring combined antioxidant, anti-inflammatory, phytoestrogenic, and osteoanabolic properties that modulate key pathways involved in bone remodeling. This narrative review aims to synthesize preclinical and clinical evidence on CQ as a potential adjunct in osteoporosis management. Preclinical studies demonstrate that CQ enhances osteoblast differentiation, collagen and matrix deposition, and mineralization, while inhibiting osteoclastogenesis and inflammatory osteoclastogenic cytokines, leading to improved bone microarchitecture, bone mineral density, and callus formation in fracture and estrogen-deficiency models. CQ phytobioactives have also been successfully integrated into advanced biomaterials, exosome-like vesicles, and self‑emulsifying drug delivery systems, improving bioavailability, osseointegration, and regenerative performance in critical-sized defects and implant models. Clinical data, although limited and heterogeneous, consistently indicate that CQ accelerates fracture healing, reduces bone pain, and increases functional recovery in maxillofacial and mandibular fractures, with favorable effects on serum calcium, alkaline phosphatase, and osteopontin expression and without major safety concerns based on available short-term data. In postmenopausal osteopenia, randomized trials show that 24‑week oral CQ stabilizes bone turnover markers and delays bone loss, albeit without short‑term gains in bone mineral density. CQ thus emerges as a multi-target, generally well-tolerated candidate for integrative osteoporosis care, particularly for early bone loss (i.e., osteopenia), fracture healing, and osteoprotection during antiresorptive drug holidays (i.e., temporary suspension of bisphosphonate therapy, particularly in the context of dental procedures). However, the absence of standardized formulations, small sample sizes, short follow-ups, and lack of head‑to‑head comparisons with standard anti‑osteoporotic therapies currently available underscore the need for long-term, multicenter randomized controlled studies using bioavailable, well-characterized CQ preparations.
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy Rossana Roncato, Samantha Perfler, Martina Gambron, Enrico Zoroddu, Monica Rosa Miozzo, Sabrina Angelini, Massimo Gennarelli, Gabriele Stocco, Valeria Conti, Amelia Filippelli, Paola Borgiani, Giuseppe Novelli, Alessio Squassina, Matteo Floris, Erika Cecchin, , Myriam Alcalay, Manuela Badiali, Marco Benati, Francesca Daniela Bertola, Gabriella Bianchino, Elisa Boldrin, Elisa Bonomi, Beatrice Bortesi, Concetta Cafiero, Daniele Calistri, Mario Capasso, Anna Paola Capra, Rita Congiu, Francesca Crosti, Matteo Curtarello, Jessica Cusato, Giulia D’Addario, Alessandra D’Urso, Emanuela De Bellis, Dario De Biase, Giovanna De Matteis, Maria Dono, Matteo Fabbri, Antonella Fabretto, Mosè Favarato, Stefano Fogli, Alessandra Franzoni, Luca Gallelli, Sabrina Rita Giglio, Mara Giordano, Giorgia Girotto, Paola Grammatico, Cristina Lapucci, Sonia Lastraioli, Barbara Mancini, Irene Mancini, Simona Natalina Mellone, Pierantonio Menna, Roberta Minari, Rossana Mineri, Giuseppe Miscio, Lorena Mosca, Antonino Moschella, Stefania Murru, Davide Nicoli, Sara Orecchia, Gloria Pessina, Claudia Rengucci, Nicoletta Sacchi, Federica Sangiuolo, Maria Scatolini, Lisa Simi, Sabine Stioui, Silvia Tabano, Luisa Toffolatti, Stefania Tommasi, Davide Trerè, Alessandro Ubiali, Sheila Ulivi, Monica Zanussi European Journal of Human Genetics, 2026 Pharmacogenetics enables personalization of drug therapy based on an individual’s genetic profile. Despite clinical relevance, implementation of pharmacogenetics remains limited. In Italy, integration is fragmented, with heterogeneous practices and a lack of national coordination. A comprehensive assessment of the current landscape is essential. A nationwide survey was conducted between January and October 2025 to map laboratories providing pharmacogenetic testing. A structured questionnaire collected data on institutional characteristics, testing workflows, pharmacogene panels, analytical methodologies, interpretation procedures, and reimbursement. Forty-nine laboratories participated (response rate: 65%). Most were part of public institutions (82%), primarily general or research hospitals. Testing was predominantly performed in medical genetics units (39%) and focused on oncology, specifically DPYD (94%) and UGT1A1 (84%) for fluoropyrimidine and irinotecan therapies. Adherence to national (SIF/AIOM) and international (CPIC/DPWG) guidelines was generally high; compliance with AMP Tier 1 analytical standards varied substantially. Pharmacological counseling was provided by only 29% of laboratories, mainly by clinical pharmacology units. Considerable heterogeneity emerged in testing platforms, bioinformatics tools, and the use of CE-IVD-certified kits. Marked geographical disparities were evident, with pharmacogenetic activity concentrated in Northern Italy. This survey provides the first national overview of pharmacogenetics implementation in Italy, revealing variability in laboratory practices, interpretation standards, and clinical integration. While oncology-related testing is widely adopted and guideline adherence is increasing, the lack of a coordinated national framework restricts consistency and equitable access. Establishing a coordinated network of pharmacogenetic laboratories with harmonized standards for testing, reporting, and education is crucial for evidence-based pharmacogenetic care.
The Role and Safety of Plant-Derived Nutraceuticals as Adjuvant Treatments for Pain Management: A Narrative Review Gianmarco Marcianò, Vincenzo Rania, Cristina Vocca, Caterina Palleria, Michele Crudo, Maurizio Evangelista, Diana Marisol Abrego-Guandique, Maria Cristina Caroleo, Luca Gallelli, Siniša Srečec Nutraceuticals, 2025 Chronic pain represents a major challenge for healthcare systems worldwide. Pharmacological agents such as opioids, gabapentinoids, and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used depending on the pain type (nociceptive, neuropathic, or nociplastic), but their use is often limited by adverse effects. Nutraceuticals and dietary supplements have emerged as potential adjuvants to conventional pain management, offering improved safety profiles. This narrative review aims to evaluate the preliminary evidence on the efficacy and safety of selected plant-derived nutraceuticals for pain management. Particular attention is given to a new fixed nutraceutical formulation containing lycopene, sulforaphane (Brassica oleracea), silymarin (extracted from Silybum marianum), reduced glutathione, escin (Aesculus hippocastanum), tryptophan, and green tea (Camellia sinensis). Although this formulation has not yet been evaluated in clinical trials, preliminary data suggest that individual components may target different pain mechanisms. None of the currently available nutraceuticals act comprehensively on all pain types. Additionally, the inclusion of hepatoprotective compounds (e.g., glutathione and silymarin) may be advantageous for patients receiving multiple medications. Current evidence on these nutraceuticals remains limited and primarily preclinical. Further randomized controlled trials are needed to confirm their efficacy and safety in human pain management.
Pregabalin and Duloxetine in Patients with Non-Nociceptive Pain: A Narrative Review Exploring the Pharmacological Effects of This Combination Gianmarco Marcianò, Maurizio Evangelista, Cristina Vocca, Vincenzo Rania, Caterina Palleria, Maria Cristina Caroleo, Riccardo Torta, Luca Gallelli Pharmaceuticals, 2025 Both neuropathic and nociplastic pain (non-nociceptive pain) are characterized by a similar pattern of clinical symptoms, including numbness, dysesthesia, tingling, and pricking. Whereas nociplastic pain results from altered nociception without indication of tissue damage or a somatosensory system lesion, neuropathic pain is caused by a disease or lesion affecting the somatosensory system. The available therapeutic options consist of antiepileptic drugs, antidepressants, and muscle relaxants. Unfortunately, symptoms are often refractory, and increasing drug dosage may lead to adverse events. In this narrative review, we searched PubMed, MEDLINE, Cochrane, and EMBASE databases from their inception up to 26 July 2025, using the key words “duloxetine,” “pregabalin,” and then ‘‘combination,’’ “nociplastic pain,” “neuropathic pain,” “efficacy,” “safety,” “pharmacology,” “pharmacokinetic,” and “pharmacodynamic.” We evaluated the role of combination therapy with duloxetine, a serotonin–norepinephrine reuptake inhibitor, and pregabalin, an antiseizure medication that acts on voltage-gated calcium channels α2δ subunit, in patients with neuropathic or nociplastic pain. The literature data indicate that combination therapy has synergistic effects, leading to fewer adverse events in specific categories of patients. Available evidence showed that combination therapy is generally not inferior to monotherapy, with slight differences in safety outcomes depending on supplementation, drug labels, and titration. These results indicate that even if not superior, combination therapy may be an alternative to monotherapy in selected patients: those who experience side effects from higher dosages of duloxetine or pregabalin and for whom symptom relief from dose reduction alone is not possible; those who use medications that interact with duloxetine; those who suffer from anxiety–depression, where pain is closely linked to mental symptoms; and those who have central neuropathic pain (often refractory).
The Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge: The Role of Drug Reconciliation Cristina Vocca, Antonio Siniscalchi, Vincenzo Rania, Cecilia Galati, Gianmarco Marcianò, Caterina Palleria, Luca Catarisano, Ilaria Gareri, Marco Leuzzi, Lucia Muraca, Rita Citraro, Giacinto Nanci, Antonio Scuteri, Rosa Candida Bianco, Iolanda Fera, Antonietta Greco, Giacomo Leuzzi, Giovambattista De Sarro, Bruno D’Agostino, Luca Gallelli Geriatrics Switzerland, 2023
Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide? Antonio Siniscalchi, Luca Gallelli, Erika Cione, Gianfranco Vasta, Antonio Guerra, Andrea Scaramuzzino, Lucia Longo, Lucia Muraca, Giovambattista De Sarro, “G & SP” Working Group, Giacomo Leuzzi, Antonio Gerace, Antonio Scuteri, Piero Vasapollo, Vincenzo Natale, Stefania Zampogna, Filippo Luciani Current Drug Safety, 2022
A Fatal Case of Tuberculosis Meningitis in Previously Health Children Manuela Colosimo, Antonella Caruso, Salvatore Nisticò, Pasquale Minchella, Antonio Cutruzzolà, Simona Paola Tiburzi, Virginia Vescio, Filippo Luciani, Gianmarco Marcianò, Luca Gallelli Pediatric Reports, 2022
The Pharmacological Treatment of Pediatric Vertigo Pasquale Viola, Gianmarco Marcianò, Alessandro Casarella, Davide Pisani, Alessia Astorina, Alfonso Scarpa, Elena Siccardi, Emanuele Basile, Giovambattista De Sarro, Luca Gallelli, Giuseppe Chiarella Children, 2022
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role Gianmarco Marcianò, Caterina Palleria, Alessandro Casarella, Vincenzo Rania, Emanuele Basile, Luca Catarisano, Cristina Vocca, Luigi Bianco, Corrado Pelaia, Erika Cione, Bruno D’Agostino, Rita Citraro, Giovambattista De Sarro, Luca Gallelli Pharmaceuticals, 2022
BA.1 Omicron Variant of SARS-CoV-2: First Case Reported in Calabria Region, Italy Cinzia Peronace, Rossana Tallerico, Manuela Colosimo, Marco De Fazio, Federica Pasceri, Ilenia Talotta, Giuseppina Panduri, Letizia Pintomalli, Rosaria Oteri, Valeria Calantoni, Maria Teresa Fiorillo, Luca Gallelli, Erika Cione, Pasquale Minchella Covid, 2022
Colchicine in Managing Skin Conditions: A Systematic Review Stefano Dastoli, Steven Paul Nisticò, Pietro Morrone, Cataldo Patruno, Antonio Leo, Rita Citraro, Luca Gallelli, Emilio Russo, Giovambattista De Sarro, Luigi Bennardo Pharmaceutics, 2022
Drug–drug interactions in vestibular diseases, clinical problems, and medico-legal implications Giulio Di Mizio, Gianmarco Marcianò, Caterina Palleria, Lucia Muraca, Vincenzo Rania, Roberta Roberti, Giuseppe Spaziano, Amalia Piscopo, Valeria Ciconte, Nunzio Di Nunno, Massimiliano Esposito, Pasquale Viola, Davide Pisani, Giovambattista De Sarro, Milena Raffi, Alessandro Piras, Giuseppe Chiarella, Luca Gallelli International Journal of Environmental Research and Public Health, 2021
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety Nicoletta Luxi, Alexia Giovanazzi, Annalisa Capuano, Salvatore Crisafulli, Paola Maria Cutroneo, Maria Pia Fantini, Carmen Ferrajolo, Ugo Moretti, Elisabetta Poluzzi, Emanuel Raschi, Claudia Ravaldi, Chiara Reno, Marco Tuccori, Alfredo Vannacci, Giovanna Zanoni, Gianluca Trifirò, Ilmiovaccino COVID19 collaborating group, Gianluca Trifirò, Ugo Moretti, Nicoletta Luxi, Alexia Giovanazzi, Giuliana Petrelli, Silvia Girotti, Elena Arzenton, Lara Magro, Riccardo Lora, David Bellantuono, Alberto Sabaini, Alberto Firenze, Donatella Zodda, Fabrizia Guidotti, Maria Zappone, Bernardo Alagna, Edoardo Spina, Paola Maria Cutroneo, Claudia Minore, Claudio Costantino, Arianna Conforto, Francesco Vitale, Ilaria Morreale, Laura Marsala, Desirè Farinella, Silvana Bavetta, Emanuel Raschi, Elisabetta Poluzzi, Maria Pia Fantini, Chiara Reno, Ester Sapigni, Anna Maria Potenza, Debora Podetti, Victoria Nikitina, Rita Ricciardelli, Nazanin Mogheiseh, Silvia Croce, Barbara Paltrinieri, Sofia Castellani, Elisa Sangiorgi, Margherita Selleri, Simona Lucchesi, Giuseppe Catucci, Denis Savini, Chiara Sacripanti, Marco Faccioli, Maria Silvia Romio, Laura Rossi, Simonetta Radici, Giovanna Negri, Lidia Fares, Chiara Ajolfi, Antonella Fadda, Antonella Chiarello, Fabio Pieraccini, Francesco Pappalardo, Marco Tuccori, Alfredo Vannacci, Roberto Bonaiuti, Claudia Ravaldi, Niccolò Lombardi, Giada Crescioli, Roberto Tessari, Emanuela Zandonà, Francesco Marchiori, Cristiano Chiamulera, Giovanna Zanoni, Gianenrico Senna, Maria Angiola Crivellaro, Mauro Cancian, Francesca Venturini, Marina Ferri, Luca Leonardi, Sabrina Orzetti, Elisabetta Caccin, Paolo Baldo, Annalisa Capuano, Concetta Rafaniello, Carmen Ferrajolo, Claudia Pagliaro, Mariangela Mercaldo, Annamaria Fucile, Annalisa di Giorgio, Michele Tari, Sonia Manna, Giuseppina Farina, Cristina Di Mauro, Ilenia De Carlo, Ilenia Senesi, Claudia Pileggi, Caterina Palleria, Luca Gallelli, Giovambattista De Sarro, Luigia Trabace, Mariagrazia Morgese, Stefania Schiavone, Paolo Tucci, Maria Bove, Francesco Lapi, Claudio Cricelli, Giorgio Racagni, Silvia Tonolo, Eugenio Leopardi, Giusi Fava, Sandro Giuffrida, Vincenza Amato, Marco Gambera, Valentina Montresor Drug Safety, 2021
Improved Efficacy of Pregabalin by Restoring Plasma Vitamin D Levels in Migraine: a Case Report Psychopharmacology Bulletin, 2019
25-hydroxy vitamin D detection using different analytic methods in patients with migraine Luca Gallelli, Andzelika Michniewicz, Erika Cione, Aida Squillace, Manuela Colosimo, Corrado Pelaia, Alessia Fazio, Stefania Zampogna, Francesco Peltrone, Rosario Iannacchero, Giovambattista De Sarro, G&SP Working Group, Monica Salerno, Giulio Di Mizio Journal of Clinical Medicine, 2019
Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice Psychopharmacology Bulletin, 2019
Severe migraine-like headache as unique symptom of steroid withdrawal syndrome betamethasone-induced in lumbar disc herniation Department Of Neurosurgery, University Of Catanzaro, Italy, Domenico Chirchiglia, Pasquale Chirchiglia, Department Of Neurosurgery, University Of Catanzaro, Italy, Giulio Di Mizio, Department Of Forensic Sciences,University Of Catanzaro, Italy, Luca Gallelli, Department Of Pharmacology, University Of Catanzaro, Italy Romanian Journal of Neurology Revista Romana De Neurologie, 2019
microRNAs to Monitor Pain-migraine and Drug Treatment Luca Gallelli, Erika Cione, Maria Cristina Caroleo, Marco Carotenuto, Pasqualina Lagana, Antonio Siniscalchi, Vincenzo Guidetti Microrna Shariqah United Arab Emirates, 2017
Dupilumab for the treatment of asthma Corrado Pelaia, Alessandro Vatrella, Luca Gallelli, Rosa Terracciano, Paolo Navalesi, Rosario Maselli, Girolamo Pelaia Expert Opinion on Biological Therapy, 2017
Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative Tommaso Cai, Luca Gallelli, Andrea Cocci, Daniele Tiscione, Paolo Verze, Michele Lanciotti, Davide Vanacore, Michele Rizzo, Mauro Gacci, Omar Saleh, Gianni Malossini, Giovanni Liguori, Carlo Trombetta, Damiano Rocco, Alessandro Palmieri, Riccardo Bartoletti, Marco Carini, Florian M. E. Wagenlehner, Kurt Naber, Vincenzo Mirone, Truls E. Bjerklund Johansen World Journal of Urology, 2017
Generalized intense pruritus during canagliflozin treatment: Is it an adverse drug reaction? Current Drug Safety, 2016
When nutraceuticals reinforce drugs side effects: A case report Roberto Russo, Luca Gallelli, Roberto Cannataro, Mariarita Perri, Antonio Calignano, Rita Citraro, Emilio Russo, Pietro Gareri, Andrea Corsonello, Giovambattista De Sarro Current Drug Safety, 2016
Estrogen Receptors and Chronic Venous Disease R. Serra, L. Gallelli, P. Perri, E.M. De Francesco, D.C. Rigiracciolo, P. Mastroroberto, M. Maggiolini, S. de Franciscis European Journal of Vascular and Endovascular Surgery, 2016
Aterofisiol® in carotid plaque evolution Raffaele Serra, Bruno Amato, Rita Compagna, Maurizio Amato, Luca Gallelli, Stefano de Franciscis Drug Design Development and Therapy, 2015
Cocaine dependence and stroke: Pathogenesis and management Antonio Siniscalchi, Antonello Bonci, Nicola Mercuri, Antonia Siena, Giovambattista Sarro, Giovanni Malferrari, Marco Diana, Luca Gallelli Current Neurovascular Research, 2015
Carotid body paragangliomas and matrix metalloproteinases Raffaele Serra, Raffaele Grande, Luca Gallelli, Pierandrea Rende, Edoardo Scarcello, Gianluca Buffone, Francesco Giuseppe Caliò, Vincenzo Gasbarro, Bruno Amato, Stefano de Franciscis Annals of Vascular Surgery, 2014
Anxiety and benzodiazepines. A Delphi method-based survey of knowledge on their pharmacology and clinical use Journal of Psychopathology, 2014
Cerebral stroke injury: The role of cytokines and brain inflammation Antonio Siniscalchi, Luca Gallelli, Giovanni Malferrari, Domenico Pirritano, Raffaele Serra, Ermenegildo Santangelo, Giovambattista De Sarro Journal of Basic and Clinical Physiology and Pharmacology, 2014
Skin rash during treatment with generic itraconazole Antonio De Vuono, Caterina Palleria, Francesca Scicchitano, Aida Squillace, Giovambattista De Sarro, Luca Gallelli Journal of Pharmacology and Pharmacotherapeutics, 2014
Application of proteomics and peptidomics to COPD Girolamo Pelaia, Rosa Terracciano, Alessandro Vatrella, Luca Gallelli, Maria Teresa Busceti, Cecilia Calabrese, Cristiana Stellato, Rocco Savino, Rosario Maselli Biomed Research International, 2014
Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic Hepatitis B patient Journal of Research in Medical Sciences, 2013
Off-label prescribing patterns of antiemetics in children: A multicenter study in Italy Davide Zanon, Luca Gallelli, Francesca Rovere, Rossella Paparazzo, Natalia Maximova, Marzia Lazzerini, Antonio Reale, Tiziana Corsetti, Salvatore Renna, Tullia Emanueli, Francesco Mannelli, Francesco Manteghetti, Liviana Da Dalt, Caterina Palleria, Nicola Banchieri, Antonio Urbino, Mario Miglietta, Giovanni Cardoni, Adriana Pompilio, Alberto Arrighini, Clara Lazzari, Gianni Messi European Journal of Pediatrics, 2013
Use of topiramate for glossodynia Antonio Siniscalchi, Luca Gallelli, Norma Maria Marigliano, Paola Orlando, Giovambattista De Sarro Pain Medicine, 2007
Mitogen-activated protein kinases and asthma Girolamo Pelaia, Giovanni Cuda, Alessandro Vatrella, Luca Gallelli, Michele Caraglia, Monica Marra, Alberto Abbruzzese, Mario Caputi, Rosario Maselli, Francesco S. Costanzo, Serafino A. Marsico Journal of Cellular Physiology, 2005
Characterization of adenosine receptors involved in adenosine-induced contraction in sensitized guinea pig isolated trachea Research Communications in Pharmacology and Toxicology, 1999
2017 RY Gold Zyp During the Italian Award of Innovation
IPA Adrion 2024
RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)
1 Gallelli L, Cione E, Aiello F. Preparato per uso topico a base di 2-(3,4-diidrossifenil) -5,7-diidrossi-4-oxo-4H-cromen-3-1 oleato, in associazione con acido ialuronico per l’uso nel trattamento di ulcere e ferite cutanee e relativo metodo di produzione. BREVETTO INDUSTRIALE. n 102017000111372 17/12/2019.
2 Microbiota Quantity Test deposito di utilità presso UIMB del 15/06/2017. 202017000066854.
3 Gallelli L, Cione E, Caroleo MC, Cannataro R. Uso di microRNA come biomarcatori per la diagnosi e/o il follow-up del danno polmonare nei soggetti esposti ad inquinanti ambientali. Number 102017000034619 18/10/2017; International Patent 2/03/2018, PCT/IB2018/052176
4 G-Screen. Dispositivo medicale per la valutazione quali-quantitativa del latte materno durante l’allattamento. Number 102016000115242 27/07/2017.
5 Paolino FM, Romano F, Gallelli L, Dominijanni A. Metodo di preparazione di sangue periferico per l’ottenimento di un preparato con alte concentrazioni di fattori di crescita. Number: 102016000011829 04/02/2016.
